

HAYNES et al
Appl. No. 09/960,717
August 21, 2003

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Cancelled).

2. (Cancelled).

2 3. (Previously Presented) The immunogen according to claim 16 wherein said ligand is an antibody, or Fab₂ or Fab fragment thereof.

3 4. (Previously Presented) The immunogen according to claim 16 wherein said ligand binds to a CCR5 binding site on gp120 and upregulates a CD4 binding site on gp120.

4 5. (Original) The immunogen according to claim 4 wherein said ligand is an antibody, or Fab₂ or Fab fragment thereof.

5 6. (Original) The immunogen according to claim 4 wherein said ligand is monoclonal antibody (mab) 17b, or Fab₂ or Fab fragment thereof, or mimic thereof.

6 7. (Previously Presented) The immunogen according to claim 16 wherein said ligand upregulates a CCR5 and a CD4 binding site on gp120.

HAYNES et al
Appl. No. 09/960,717
August 21, 2003

7 8. (Original) The immunogen according to claim 7 wherein said ligand is an antibody, or Fab₂ or Fab fragment thereof.

8 9. (Original) The immunogen according to claim 7 wherein said ligand binds to a site on gp120 to which mab A32 binds.

9 10. (Original) The immunogen according to claim 9 wherein said ligand is mab A32, or Fab₂ or Fab fragment thereof, or mimic thereof.

11. (Cancelled).

10 12. (Previously Presented) The immunogen according to claim 10 wherein said protein is in soluble form.

11 13. (Previously Presented) The immunogen according to claim 16 wherein said protein is associated with a cell vesicle or liposome.

14. (Cancelled).

12 15. (Previously Presented) The immunogen according to claim 16 wherein gp120, gp41 and said ligand are crosslinked.

16. (Currently Amended) An isolated immunogen comprising an HIV envelope protein bound to a ligand, which ligand upregulates at least one of the CD4

HAYNES et al
Appl. No. 09/960,717
August 21, 2003

binding site and the CCR5 binding site on said protein,
wherein said protein is gp120 noncovalently bound to gp41, and
wherein said immunogen further comprises an HR-2 peptide bound to said protein.

¹³ ¹⁷ 17. (Original) The immunogen according to claim ¹⁶ wherein gp120, gp41,
said ligand and said HR-2 peptide are crosslinked.

18-27. (Cancelled).

¹⁴ ¹⁸ 28. (New) The immunogen according to claim ¹⁶ wherein gp120 is
noncovalently bound to gp41.